时隔4年，葛兰再限购

Core Viewpoint - Multiple high-performing funds under China Europe Fund have announced purchase restrictions to ensure stable fund operations and protect the interests of fund shareholders [1][3][7]. Fund Purchase Restrictions - On August 9, China Europe Medical Innovation Fund announced a purchase limit of 100,000 yuan per day per fund account, effective from August 11, to maintain stability and protect shareholder interests [1][3]. - The fund's combined scale for Class A and Class C shares was reported at 8.114 billion yuan as of June 30 [1]. - Similar restrictions were previously implemented for another fund managed by the same manager, China Europe Medical Health, since January 2021 [2]. Performance Metrics - As of August 8, the China Europe Medical Innovation Fund achieved a year-to-date return of 62.28% and a one-year return of 80.12%, ranking in the top 2 among similar funds [4]. - Other funds managed by China Europe Fund, such as China Europe Science and Technology Theme Fund and China Europe Intelligent Manufacturing Mixed Fund, have also announced purchase limits due to strong performance, with returns of 84.33% and over 140% respectively [7]. Investment Strategy - The fund manager, Ge Lan, remains optimistic about the innovative drug sector, emphasizing the growing global competitiveness of domestic companies in areas like ADC, dual antibodies, and peptides [5]. - The domestic policy environment is also seen as supportive, with ongoing improvements in research efficiency, quality, and diversified payment mechanisms, which are expected to benefit innovative drug companies [5]. Industry Trends - The trend of imposing purchase limits among high-performing funds reflects a proactive approach by fund companies to control scale during favorable market conditions, ensuring effective investment strategies and stable fund operations [7]. - Approximately 80 actively managed equity funds have announced purchase restrictions since July, indicating a broader industry trend towards managing fund sizes in response to market performance [7].